Montserrat MuÃ±oz

List of Publications by Year
in descending order

105 papers	5,097 citations	101543 36 h-index	95266 68 g-index
108 all docs	108 docs citations	108 times ranked	7680 citing authors

#	Article	IF	Citations
1	Gene expression profiles of breast cancer metastasis according to organ site. Molecular Oncology, 2022, 16, 69-87.	4.6	24
2	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors-Integrating electronic data collection into clinical practice. Cancer Research, 2022, 82, P4-11-28-P4-11-28.	0.9	0
3	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. Cancer Research, 2022, 82, P4-10-04-P4-10-04.	0.9	2
4	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. Cancer Research, 2022, 82, P4-07-08-P4-07-08.	0.9	2
5	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. European Journal of Cancer, 2022, 168, 12-24.	2.8	9
6	Artificial intelligence supporting cancer patients across Europeâ€"The ASCAPE project. PLoS ONE, 2022, 17, e0265127.	2.5	9
7	Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).. Journal of Clinical Oncology, 2022, 40, 1019-1019.	1.6	1
8	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptorâ€"Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Antiâ€"HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125.	7.0	9
9	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. Npj Breast Cancer, 2021, 7, 8.	5.2	14
10	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. Journal of Clinical Oncology, 2021, 39, 3060-3060.	1.6	0
11	CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.. Journal of Clinical Oncology, 2021, 39, 1014-1014.	1.6	1
12	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine, 2021, 69, 103451.	6.1	7
13	Trajectories of alcohol consumption during life and the risk of developing breast cancer. British Journal of Cancer, 2021, 125, 1168-1176.	6.4	17
14	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 33-43.	10.7	105
15	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1902.	3.7	29
16	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. Scientific Reports, 2020, 10, 7741.	3.3	9
17	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	10.7	52
18	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. Nutrients, 2020, 12, 3132.	4.1	11

#	Article	IF	Citations
19	Implementing preoperative endocrine therapy in breast cancer. Lancet Oncology, The, 2020, 21, 1390-1392.	10.7	0
20	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research, 2020, 22, 45.	5.0	175
21	Phase III study to evaluate patientâ€™s preference of subcutaneous versus intravenous trastuzumab in HER2â€positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012â€07). European Journal of Cancer Care, 2020, 29, e13253.	1.5	5
22	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	7.7	92
23	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	12.8	67
24	Development and validation of a sexual relations satisfaction scale in patients with breast cancer â€” â€œSEXSAT-Qâ€. Health and Quality of Life Outcomes, 2019, 17, 143.	2.4	4
25	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. European Journal of Radiology, 2019, 117, 132-139.	2.6	10
26	Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a singleâ€arm trial. Journal of Human Nutrition and Dietetics, 2019, 32, 468-479.	2.5	9
27	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2â^) early breast cancer (EBC): results from the GEICAM/2006â€“10 study. Breast Cancer Research and Treatment, 2019, 177, 115-125.	2.5	20
28	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	2.8	8
29	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. Scientific Reports, 2019, 9, 3904.	3.3	23
30	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. Environment International, 2019, 122, 389-399.	10.0	28
31	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Medicine, 2019, 17, 8.	5.5	28
32	Abstract P2-08-17: Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study. Cancer Research, 2019, 79, P2-08-17-P2-08-17.	0.9	1
33	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology, 2018, 20, 211-221.	10.3	98
34	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 63-70.	7.7	79
35	Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors. European Journal of Cancer Care, 2018, 27, e12861.	1.5	20
36	Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) Â± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.. Journal of Clinical Oncology, 2018, 36, 1013-1013.	1.6	7

#	Article	IF	Citations
37	A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. Journal of Clinical Oncology, 2018, 36, TPS1114-TPS1114.	1.6	3
38	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. Journal of Clinical Oncology, 2018, 36, 1521-1521.	1.6	8
39	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 545-554.	10.7	250
40	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research, 2017, 77, 2213-2221.	0.9	168
41	A PAM50-Based Chemoendocrine Score for Hormone Receptorâ€“Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research, 2017, 23, 3035-3044.	7.0	28
42	Physical activity and breast cancer risk by pathological subtype. Gynecologic Oncology, 2017, 144, 577-585.	1.4	34
43	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. Oncologist, 2017, 22, 1301-1308.	3.7	13
44	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clinical and Translational Oncology, 2017, 19, 341-356.	2.4	10
45	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget, 2017, 8, 73144-73153.	1.8	24
46	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. Journal of Clinical Oncology, 2017, 35, 3030-3038.	1.6	90
47	MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells. Oncotarget, 2017, 8, 83384-83406.	1.8	23
48	Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).. Journal of Clinical Oncology, 2017, 35, 1023-1023.	1.6	5
49	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. Oncotarget, 2017, 8, 21930-21937.	1.8	17
50	Ingested Nitrate and Breast Cancer in the Spanish Multicase-Control Study on Cancer (MCC-Spain). Environmental Health Perspectives, 2016, 124, 1042-1049.	6.0	19
51	The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. PLoS ONE, 2016, 11, e0159672.	2.5	32
52	SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). Clinical and Translational Oncology, 2016, 18, 1229-1236.	2.4	51
53	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. Journal of the Academy of Nutrition and Dietetics, 2016, 116, 1914-1924.e6.	0.8	26
54	Prognostic Value of Intrinsic Subtypes in Hormone Receptorâ€“Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncology, 2016, 2, 1287.	7.1	96

#	Article	IF	Citations
55	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. Journal of Clinical Oncology, 2016, 34, 3033-3033.	1.6	0
56	Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.. Journal of Clinical Oncology, 2016, 34, e12504-e12504.	1.6	0
57	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine, 2015, 13, 303.	5.5	113
58	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. Journal of Clinical Oncology, 2015, 33, 1045-1052.	1.6	108
59	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Journal of Clinical Oncology, 2015, 33, 3788-3795.	1.6	56
60	Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 2015, 24, S26-S35.	2.2	735
61	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. Oncologist, 2015, 20, 111-112.	3.7	20
62	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. PLoS ONE, 2015, 10, e0126096.	2.5	56
63	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	6.4	239
64	Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors. Critical Reviews in Oncology/Hematology, 2014, 89, 62-72.	4.4	41
65	Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. Medical Oncology, 2014, 31, 783.	2.5	47
66	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Breast Cancer Research and Treatment, 2014, 143, 507-515.	2.5	60
67	Trastuzumab in small tumours and in elderly women. Cancer Treatment Reviews, 2014, 40, 41-47.	7.7	15
68	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. Breast, 2014, 23, 710-720.	2.2	37
69	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology, 2014, 32, 11107-11107.	1.6	1
70	Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. Journal of Clinical Oncology, 2014, 32, 1602-1602.	1.6	0
71	Costâ€“utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 381-391.	1.4	16
72	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. Journal of Clinical Oncology, 2013, 31, 2593-2599.	1.6	52

#	Article	IF	Citations
73	Infrequent Loss of Luminal Differentiation in Ductal Breast Cancer Metastasis. PLoS ONE, 2013, 8, e78097.	2.5	6
74	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity.. , 2013, , .		0
75	Circulating levels of HER-2/neu oncoprotein in breast cancer. Clinical Chemistry and Laboratory Medicine, 2012, 50, 5-21.	2.3	27
76	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology, The, 2011, 12, 369-376.	10.7	73
77	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004â€“05 study. Annals of Oncology, 2011, 22, 2591-2596.	1.2	28
78	Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009â˜05 study.. Journal of Clinical Oncology, 2011, 29, 1008-1008.	1.6	1
79	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biology, 2010, 31, 171-180.	1.8	61
80	Quality of life during treatment in young women with breast cancer. Breast Cancer Research and Treatment, 2010, 123, 75-77.	2.5	14
81	Predicting Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Involvement: Evaluation of Two Scoring Systems. Breast Journal, 2010, 16, 134-140.	1.0	21
82	Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clinical Chemistry, 2010, 56, 1148-1157.	3.2	70
83	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. New England Journal of Medicine, 2010, 363, 2200-2210.	27.0	169
84	Current perspectives of treatment of ductal carcinoma in situ. Cancer Treatment Reviews, 2010, 36, 507-517.	7.7	18
85	Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.. Journal of Clinical Oncology, 2010, 28, 1143-1143.	1.6	1
86	0145 First safety data from a randomised phase III trial comparing adjuvant epirubicinâ€“cyclophosphamide â† docetaxel (EC â† T) vs ET â† capecitabine (X) in N+ operable breast cancer (BC). Breast, 2009, 18, S55.	2.2	1
87	18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1551-1557.	6.4	104
88	Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. British Journal of Cancer, 2009, 100, 442-449.	6.4	33
89	Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology, 2009, 20, 454-459.	1.2	13
90	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treatment Reviews, 2008, 34, 701-709.	7.7	21

#	Article	IF	Citations
91	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. Clinical Cancer Research, 2008, 14, 811-816.	7.0	113
92	Preoperative Staging of Large Primary Breast Cancer With [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging Procedures. Journal of Clinical Oncology, 2008, 26, 4746-4751.	1.6	259
93	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treatment Reviews, 2007, 33, 474-483.	7.7	16
94	The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials. Clinical Breast Cancer, 2007, 7, 764-774.	2.4	4
95	Current controversies in the management of early breast cancer. Clinical and Translational Oncology, 2007, 9, 375-84.	2.4	3
96	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. Breast Cancer Research, 2005, 7, 1.	5.0	0
97	Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results. Journal of Clinical Oncology, 2005, 23, 735-735.	1.6	1
98	Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. International Journal of Radiation Oncology Biology Physics, 2004, 60, 715-721.	0.8	75
99	Serial Topoisomerase II Expression in Primary Breast Cancer and Response to Neoadjuvant Anthracycline-Based Chemotherapy. Oncology, 2004, 66, 388-394.	1.9	48
100	Gender, age, socio-demographic and lifestyle factors associated with major dietary patterns in the Spanish Project SUN (Seguimiento Universidad de Navarra). European Journal of Clinical Nutrition, 2003, 57, 285-292.	2.9	164
101	Scintigraphic Evolution of a Breast Cancer with Tc-99m MIBI Scintimammography. Clinical Nuclear Medicine, 2000, 25, 701-703.	1.3	0
102	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Research and Treatment, 1998, 51, 109-119.	2.5	104
103	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. Journal of Pathology, 1998, 184, 265-271.	4.5	46
104	CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. , 1997, 182, 160-166.		63
105	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. British Journal of Cancer, 1996, 74, 1126-1131.	6.4	64